The startup operates a drug discovery platform that combines the tumor-killing effects of chemotherapy with targeted therapies to enhance treatment options for relapsed and refractory lymphomas and challenging solid tumors. This approach aims to improve therapeutic outcomes for cancer patients facing limited treatment alternatives.
Funding
$32M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers, particularly relapsed and refractory lymphomas and challenging solid tumors, have limited effective treatment options, leading to poor outcomes for patients. Cancer cells often develop resistance to apoptosis, hindering the effectiveness of traditional chemotherapy and targeted therapies.
Solution
Bantam Pharma is developing first-in-class, orally available small molecule therapeutics designed to restore apoptosis in cancer cells by targeting mitochondrial dynamics. Their lead candidate, BTM-3566, has demonstrated significant in vitro and in vivo anti-cancer activity against hematologic and solid tumors, particularly Diffuse Large B-cell Lymphoma (DLBCL), inducing durable and complete regression in primary tumor models. This novel mechanism aims to destroy cancer cells from the inside, offering a new approach to treating difficult-to-treat cancers and improving patient outcomes. By restoring the cancer cells' ability to undergo cell death, Bantam Pharma's technology generates anti-tumor effects.
Target Audience
The primary target audience includes patients with relapsed and refractory lymphomas and challenging solid tumors, as well as oncologists and hematologists seeking new treatment options for these cancers.
Features
- Novel small molecule compound targeting mitochondrial dynamics to restore apoptosis in cancer cells.
- Orally available therapeutic for convenient administration.
- Demonstrated in vitro and in vivo activity against DLBCL and other hematologic and solid tumors.
- Induces durable and complete regression in primary tumor models in preclinical studies.
- Designed to overcome resistance to traditional chemotherapy and targeted therapies.